AUS
NZ
UK
CA
USA
IND
4DMedical Limited (ASX:4DX), an Australian medical imaging technology firm, has applied for quotation on the ASX of 14,436 newly issued ordinary fully paid shares. These shares were granted to a consultant on 1 July 2026 as payment for services instead of cash, valued at an implied price of $4.08 per share according to the company’s update. This issuance was initially disclosed through an Appendix 3B lodged in July 2025, and the company has confirmed that no further shares remain to be issued under this arrangement, concluding the matter.<\/p> <\/div>
Key Points<\/h3>
- Company: 4DMedical Limited (ASX:4DX)<\/li>
- 14,436 ordinary fully paid shares issued on 1 July 2026, now applied for quotation<\/a> on ASX<\/li>
- Shares issued as payment for consulting services in lieu of cash, valued at $4.08 each<\/li>
- Total quoted ordinary shares on issue increase to 597,573,557 following quotation<\/li>
- Transaction finalizes the securities issuance flagged in the Appendix 3B lodged 28 July 2025<\/li>
- Investors should monitor future consulting or operational updates as 4DMedical advances its lung imaging technology platform<\/li>
<\/ul>
<\/div>
4DMedical Issues Shares at $4.08 Each to Settle Consultant Fees Without Cash Payment<\/h2>
This update details a strategic move by 4DMedical to compensate a consultant with equity rather than cash. The 14,436 shares were issued at an implied value of $4.08 per share, equating to approximately $58,899 in consulting fees. The company did not disclose the consultant’s identity or the nature of the services in this announcement.<\/p>
Issuing shares instead of cash is common among growth-stage listed companies managing cash flow while investing in commercialization and product development. For 4DMedical, which is focused on expanding adoption of its proprietary XV Technology lung imaging platform, settling fees with equity helps conserve cash, serving as a prudent capital<\/a> management strategy. The company provided no further commentary on the rationale beyond the filing.<\/p>
Link Between the 1 July 2026 Share Issuance and the July 2025 Appendix 3B<\/h2>
The current quotation application finalizes a process first disclosed on 28 July 2025, when 4DMedical lodged an Appendix 3B titled "New — Proposed issue of securities — 4DX." That notice alerted the market to a forthcoming securities issuance, either through a placement<\/a> or similar mechanism.<\/p>
The recent Appendix 2A filing confirms the shares have now been issued and ASX listing is requested. Importantly, 4DMedical confirmed no further securities remain to be issued under this arrangement, providing investors certainty that the consulting fee settlement is complete and no additional dilution from this transaction is expected.<\/p>
Ordinary Shares on Issue Now Total 597,573,557 After Quotation<\/h2>
With the addition of 14,436 shares, 4DMedical’s total quoted ordinary fully paid shares on issue have risen to 597,573,557. This figure is automatically updated by the ASX system and may not fully reflect the company’s current issued capital<\/a> if other transactions are processing simultaneously. Investors should refer to the latest capital structure<\/a> disclosures for the most accurate details.<\/p>
The incremental dilution from this issuance is approximately 0.002%, a negligible impact for existing shareholders. However, considering the broader capital structure, including numerous unquoted options<\/a> and performance rights, investors should remain aware of potential dilution from these instruments.<\/p>
Comprehensive Capital Structure Including Options and Performance Rights<\/h2>
Beyond quoted shares, 4DMedical holds a significant number of unquoted securities. The filing reports 22,795,383 listed options expiring 1 September 2027 (ticker 4DXOB). Unquoted securities include 804,999 performance rights (4DXAX) and five tranches of options with varying expiry dates and exercise prices.<\/p>
The unquoted options comprise: 25,456,437 options expiring on various dates and prices (4DXAG); 2,133,333 options expiring 15 March 2027 at $1.20 exercise price (4DXAJ); 1,306,100 options expiring 3 November 2027 at $1.60 (4DXAW); 4,568,275 options expiring 28 November 2029 at $0.8448 (4DXAAA); and 775,339 options expiring 30 June 2028 at $0.7534 (4DXAY). Together, these represent a potential source of future share issuance that investors should factor into long-term dilution assessments.<\/p>
Implications of the $4.08 Per Share Valuation for 4DMedical’s Equity<\/h2>
The $4.08 per share valuation used to settle consulting fees is a notable figure reflecting the company’s estimate of security value as required by the Appendix 2A process. It does not necessarily represent a market transaction price derived from an open or competitive process, so investors should interpret it accordingly.<\/p>
4DMedical Issues Shares at $4.08 Each to Settle Consultant Fees Without Cash Payment<\/h2>
This update details a strategic move by 4DMedical to compensate a consultant with equity rather than cash. The 14,436 shares were issued at an implied value of $4.08 per share, equating to approximately $58,899 in consulting fees. The company did not disclose the consultant’s identity or the nature of the services in this announcement.<\/p>
Issuing shares instead of cash is common among growth-stage listed companies managing cash flow while investing in commercialization and product development. For 4DMedical, which is focused on expanding adoption of its proprietary XV Technology lung imaging platform, settling fees with equity helps conserve cash, serving as a prudent capital<\/a> management strategy. The company provided no further commentary on the rationale beyond the filing.<\/p>
The current quotation application finalizes a process first disclosed on 28 July 2025, when 4DMedical lodged an Appendix 3B titled "New — Proposed issue of securities — 4DX." That notice alerted the market to a forthcoming securities issuance, either through a placement<\/a> or similar mechanism.<\/p>
The recent Appendix 2A filing confirms the shares have now been issued and ASX listing is requested. Importantly, 4DMedical confirmed no further securities remain to be issued under this arrangement, providing investors certainty that the consulting fee settlement is complete and no additional dilution from this transaction is expected.<\/p>
With the addition of 14,436 shares, 4DMedical’s total quoted ordinary fully paid shares on issue have risen to 597,573,557. This figure is automatically updated by the ASX system and may not fully reflect the company’s current issued capital<\/a> if other transactions are processing simultaneously. Investors should refer to the latest capital structure<\/a> disclosures for the most accurate details.<\/p>
The incremental dilution from this issuance is approximately 0.002%, a negligible impact for existing shareholders. However, considering the broader capital structure, including numerous unquoted options<\/a> and performance rights, investors should remain aware of potential dilution from these instruments.<\/p>
Beyond quoted shares, 4DMedical holds a significant number of unquoted securities. The filing reports 22,795,383 listed options expiring 1 September 2027 (ticker 4DXOB). Unquoted securities include 804,999 performance rights (4DXAX) and five tranches of options with varying expiry dates and exercise prices.<\/p>
The unquoted options comprise: 25,456,437 options expiring on various dates and prices (4DXAG); 2,133,333 options expiring 15 March 2027 at $1.20 exercise price (4DXAJ); 1,306,100 options expiring 3 November 2027 at $1.60 (4DXAW); 4,568,275 options expiring 28 November 2029 at $0.8448 (4DXAAA); and 775,339 options expiring 30 June 2028 at $0.7534 (4DXAY). Together, these represent a potential source of future share issuance that investors should factor into long-term dilution assessments.<\/p>
The $4.08 per share valuation used to settle consulting fees is a notable figure reflecting the company’s estimate of security value as required by the Appendix 2A process. It does not necessarily represent a market transaction price derived from an open or competitive process, so investors should interpret it accordingly.<\/p>
Link Between the 1 July 2026 Share Issuance and the July 2025 Appendix 3B<\/h2>
Ordinary Shares on Issue Now Total 597,573,557 After Quotation<\/h2>
Comprehensive Capital Structure Including Options and Performance Rights<\/h2>
Implications of the $4.08 Per Share Valuation for 4DMedical’s Equity<\/h2>
